Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €49.33 EUR
Change Today -0.71 / -1.41%
Volume 0.0
8AK On Other Exchanges
As of 10:37 AM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Connaught House

1 Burlington Road

Dublin, 4


Phone: 353 1 772 8000


3831. ALKS 5461 ALKS 5461 is a proprietary combination of ALKS 33 and buprenorphine that the company is developing to be a non-addictive therapy for the treatment of major depressive disorder (MDD) in patients who have an inadequate response to standard antidepressant therapies. In 2013, the company announced positive results from a phase 2 study in which ALKS 5461 met its primary endpoint, met key secondary endpoints and demonstrated significant reduction in depressive symptoms versus placebo. In 2013, the company announced that it had completed its end-of-Phase 2 interactions with the FDA and that the FDA had granted ALKS 5461 Fast Track status for the adjunctive treatment of MDD in patients with an inadequate response to standard therapies. ALKS 3831 ALKS 3831 is a proprietary investigational medicine designed as a spectrum treatment for schizophrenia. ALKS 3831 is composed of ALKS 33, an oral opioid modulator, in combination with the established antipsychotic drug olanzapine, which is generally available under the name ZYPREXA (olanzapine). ALKS 3831 is designed to attenuate olanzapine-induced metabolic side effects, including weight gain, and to have utility in patients with schizophrenia exacerbated by alcohol use disorders. In 2013, the company announced the initiation of a double-blind, active-controlled, dose-ranging phase 2 study of ALKS 3831 in patients with schizophrenia. In addition to safety and tolerability, the phase 2 study is designed to evaluate the impact of ALKS 3831 on weight and other metabolic factors and to confirm the attenuation of olanzapine-induced weight gain observed in the phase 1 study of ALKS 3831. Monomethyl Fumarate (MMF) Prodrug ALKS 8700 ALKS 8700 is a proprietary, small-molecule prodrug of MMF for the treatment of multiple sclerosis. It is designed to convert to MMF in the body and to offer differentiated dosing and tolerability as compared to the marketed dimethyl fumarate prodrug, TECFIDERA. ALKS 7106 ALKS 7106 is the company’s proprietary small-molecule product candidate derived from its opioid modulator platform. ALKS 7106 is a potent oral opioid analgesic designed for the treatment of pain with intrinsically low potential for abuse and overdose death, two liabilities associated with opioid medicines. RDB 1419 In 2013, the company presented preclinical data showing that RDB 1419, a proprietary biologic cancer immunotherapy candidate based on interleukin-2 and its receptors, preferentially expanded the number of tumor-killing cells involved in immunotherapeutic effects on cancer. Additional preclinical data demonstrated that RDB 1419 inhibited lung metastases in a model of lung cancer. RDB 1419 was engineered using the company’s proprietary fusion protein technology platform to modulate the natural mechanism of action of a biologic. Other A phase 3 clinical research program for a three-month formulation of INVEGA SUSTENNA was initiated by Janssen Research & Development, LLC in 2012. AstraZeneca is developing line extensions for BYDUREON, including a dual-chamber pen device, and weekly and monthly suspension formulations using the company’s proprietary technology for extended-release microspheres. In January 2014, AstraZeneca stated that they expect the BYDUREON dual-chamber pen to be approved in the U.S. in the second quarter of 2014 and in the EU in the fourth quarter of 2014, and that they plan to file for approval of the dual-chamber pen in Japan during the second quarter of 2014. In 2013, AstraZeneca announced its expectation to file for approval of the BYDUREON once-weekly suspension in the U.S. and EU in 2015. Other Arrangements The company has an asset purchase and license agreement and equity investment agreement with Civitas Therapeutics, Inc. Marketing, Sales and Distribution The company is responsible for the marketing of VIVITROL in the U.S. It focuses its sales and marketing efforts on specialist physicians in private practice and in public treatment systems. The company provides customer service and other related programs for its product, such as product-specific Websites, insurance research services and order, deli


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
8AK:GR €49.33 EUR -0.71

8AK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cosmo Pharmaceuticals SA SFr.158.10 CHF +0.50
Depomed Inc $23.69 USD +0.3345
Emergent Biosolutions Inc $30.98 USD +0.354
Jazz Pharmaceuticals PLC $176.43 USD +0.01
Pacira Pharmaceuticals Inc/DE $67.15 USD +1.37
View Industry Companies

Industry Analysis


Industry Average

Valuation 8AK Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.1x
Price/Book 6.0x
Price/Cash Flow 350.5x
TEV/Sales 11.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALKERMES PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at